Methodological Aspects of Minimal Residual Disease Assessment by Flow Cytometry in Acute Lymphoblastic Leukemia: A French Multicenter Study

被引：38

作者：

Fossat, Chantal ^{[1
]}

Roussel, Mikael ^{[2
]}

Arnoux, Isabelle ^{[1
]}

Asnafi, Vahid ^{[3
]}

Brouzes, Chantal ^{[3
]}

Garnache-Ottou, Francine ^{[4
]}

Jacob, Marie-Christine ^{[5
]}

Kuhlein, Emilienne ^{[6
]}

Macintyre-Davi, Elizabeth ^{[3
]}

Plesa, Adriana ^{[7
]}

Robillard, Nelly ^{[8
]}

Tkaczuk, Jean ^{[6
]}

Ifrah, Norbert ^{[9
]}

Dombret, Herve ^{[10
]}

Bene, Marie C. ^{[8
]}

Baruchel, Andre ^{[11
]}

Garand, Richard ^{[8
]}

机构：

[1] Hop Enfants La Timone, Hematol Lab, Marseille, France

[2] CHU Rennes, Hematol Lab, Rennes, France

[3] Hop Necker Enfants Malad, AP HP, Dept Hematol, Paris, France

[4] EFS Besancon, Hematol Lab, Besancon, France

[5] CHU Grenoble, Immunol Lab, F-38043 Grenoble, France

[6] CHU Toulouse, Immunol Lab, Toulouse, France

[7] Hop Edouard Herriot, Hosp Civils Lyon, Hematol Lab, Lyon, France

[8] CHU Nantes, Hematol Lab, F-44000 Nantes, France

[9] CHU Angers, Dept Hematol, Angers, France

[10] Hop St Louis, AP HP, Dept Hematol, Paris, France

[11] Hop Robert Debre, AP HP, Dept Hematol, F-75019 Paris, France

来源：

CYTOMETRY PART B-CLINICAL CYTOMETRY | 2015年 / 88卷 / 01期

关键词：

acute lymphoblastic leukemia; minimal residual disease; leukemia associated immunophenotypic pattern; flow cytometry; bone marrow; peripheral blood; NORMAL BONE-MARROW; PERIPHERAL-BLOOD; PROGNOSTIC-FACTORS; INDUCTION THERAPY; FOLLOW-UP; QUANTIFICATION; CHILDREN; FRALLE; EORTC;

D O I：

10.1002/cyto.b.21195

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

BackgroundMinimal residual disease (MRD) assessment provides a powerful prognostic factor for therapeutic stratification in acute lymphoblastic leukemia (ALL). Multiparameter flow cytometry (MFC) has the potential for a rapid and sensitive identification of high risk patients. Our group has previously published that MRD levels analyzed by clone specific Ig/TcR-QPCR and MFC were concordant at a sensitivity of 10(-4). Here we report the MFC methodological aspects from this multi-center experience. MethodsMRD was assessed by MFC in 1030 follow-up samples from 265 pediatric and adult patients with de novo ALL treated in the FRALLE, EORTC, or GRALL clinical trials. MRD assessment as applied by the eight participating MFC laboratories is described in detail regarding cell preparation, leukemia-associated immunophenotype (LAIP) markers and data analysis. Samples were obtained from bone marrow (BM) and peripheral blood (PB). Immunostaining was performed after erythrocyte lysis or Ficoll enrichment. ResultsThis study confirms the applicability of MFC-based MRD assessment in 97% of patients with ALL at the 10(-4) cut-off. MRD values after Ficoll enrichment and erythrocyte lysis were found comparable. Higher MRD values were obtained in BM than in PB, especially for B-lineage ALL. ConclusionsMeasurement of MRD by MFC at the 10(-4) cut-off is applicable within a few hours for almost all patients and using a comparable analytical strategy allows for multicenter collaborative studies. The method can be introduced in a strategy aimed at defining the risk of failure of patients with childhood or adult ALL. (c) 2014 International Clinical Cytometry Society

引用

页码：21 / 29

页数：9

共 33 条

[1] Four- and Five-Color Flow Cytometry Analysis of Leukocyte Differentiation Pathways in Normal Bone Marrow: A Reference Document Based on a Systematic Approach by the GTLLF and GEIL [J].

Arnoulet, Christine ;

Bene, Marie C. ;

Durrieu, Francoise ;

Feuillard, Jean ;

Fossat, Chantal ;

Husson, Bernard ;

Jouault, Helene ;

Maynadie, Marc ;

Lacombe, Francis .

CYTOMETRY PART B-CLINICAL CYTOMETRY, 2010, 78B (01) :3-10

[2]

BENE MC, 1995, LEUKEMIA, V9, P1783

[3] Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia [J].

Björklund, E ;

Mazur, J ;

Söderhäll, S ;

Porwit-MacDonald, A .

LEUKEMIA, 2003, 17 (01) :138-148

[4] Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study [J].

Borowitz, Michael J. ;

Devidas, Meenakshi ;

Hunger, Stephen P. ;

Bowman, W. Paul ;

Carroll, Andrew J. ;

Carroll, William L. ;

Linda, Stephen ;

Martin, Paul L. ;

Pullen, D. Jeanette ;

Viswanatha, David ;

Willman, Cheryl L. ;

Winick, Naomi ;

Camitta, Bruce M. .

BLOOD, 2008, 111 (12) :5477-5485

[5] Flow Cytometric Differential of Leukocyte Populations in Normal Bone Marrow: Influence of Peripheral Blood Contamination [J].

Brooimans, R. A. ;

Kraan, J. ;

van Putten, W. ;

Cornelissen, J. J. ;

Lowenberg, B. ;

Gratama, J. W. .

CYTOMETRY PART B-CLINICAL CYTOMETRY, 2009, 76B (01) :18-26

[6] Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008 [J].

Brueggemann, M. ;

Schrauder, A. ;

Raff, T. ;

Pfeifer, H. ;

Dworzak, M. ;

Ottmann, O. G. ;

Asnafi, V. ;

Baruchel, A. ;

Bassan, R. ;

Benoit, Y. ;

Biondi, A. ;

Cave, H. ;

Dombret, H. ;

Fielding, A. K. ;

Foa, R. ;

Goekbuget, N. ;

Goldstone, A. H. ;

Goulden, N. ;

Henze, G. ;

Hoelzer, D. ;

Janka-Schaub, G. E. ;

Macintyre, E. A. ;

Pieters, R. ;

Rambaldi, A. ;

Ribera, J-M ;

Schmiegelow, K. ;

Spinelli, O. ;

Stary, J. ;

von Stackelberg, A. ;

Kneba, M. ;

Schrappe, M. ;

van Dongen, J. J. M. .

LEUKEMIA, 2010, 24 (03) :521-535

[7] Has MRD monitoring superseded other prognostic factors in adult ALL? [J].

Brueggemann, Monika ;

Raff, Thorsten ;

Kneba, Michael .

BLOOD, 2012, 120 (23) :4470-4481

[8] Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia [J].

Campana, D ;

Coustan-Smith, E .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2002, 15 (01) :1-19

[9] DETECTION OF RESIDUAL LEUKEMIA WITH IMMUNOLOGICAL METHODS - TECHNICAL DEVELOPMENTS AND CLINICAL IMPLICATIONS [J].

CAMPANA, D ;

FREITAS, RO ;

COUSTANSMITH, E .

LEUKEMIA & LYMPHOMA, 1994, 13 :31-34

[10] Minimal residual disease monitoring in childhood acute lymphoblastic leukemia [J].

Campana, Dario .

CURRENT OPINION IN HEMATOLOGY, 2012, 19 (04) :313-318

← 1 2 3 4 →